Fresh analysis indicates that individuals who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who end conventional lifestyle programs.
Published data in a leading health publication demonstrates that while obese individuals often shed substantial amounts of their body weight while using the jabs, the weight comes back at an average rate of 0.8 kg per month upon discontinuation.
"Individuals purchasing such medications need to be aware of the risk of quick weight regain when the medication concludes," stated expert Dr. Susan Jebb.
That rate of regain suggests a reversion to pre-treatment weight within about a year and a half.
Comparing Approaches
The study, which examined 37 of studies involving thousands of patients, contrasted the results of GLP-1 agonists with conventional dieting.
Scientists note that people who lose weight through dieting usually see a slower creep back—perhaps 100 grams monthly—once they finish.
Understanding the Quick Rebound
Nutrition scientists believe the mechanism of the jabs explains the heightened rebound.
These medications copy a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Long-term administration of the hormone concentrations far above than the body's typical production might result in the system to generate a reduced amount of its endogenous GLP-1, and may also reduce sensitivity to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this medication results in appetite is no longer kept in check, making excessive eating a significant risk."
A Lifelong Issue?
Health authorities suggest the jabs for people with weight-linked health risks, alongside recommended lifestyle changes.
Professionals contend that, given the significant potential of relapse, the therapy is often long-term.
This perspective is supported by pharmaceutical companies, who state that the findings "underscore the long-term nature of obesity," similar to managing diseases like high blood pressure.
User Accounts
Individuals who have come off the medication explain a intense resurgence of appetite.
"I experienced something flipping and I was suddenly extremely hungry," said one woman.
This challenge is worsened if patients have not established sustainable dietary or behavioural modifications during therapy.
Widespread Interest
Recent estimates show that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow.
- Adoption is higher among females than males.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
Finally, clinicians emphasize that while these medications are potent tools for shedding pounds, they are not a standalone solution and maintained weight loss likely depends on integrated behavioural changes.
